Beckman Coulter Pulls Troponin Assays From Market
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter is pulling a portion of its cardiac troponin assays from the market in response to FDA scrutiny, the firm said April 12
You may also be interested in...
News In Brief
Orthofix realigns business units. Globus Medial has to pay DePuy $16 million for patent infringement. More news.
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.